In 2023, the Hong Kong Stock Exchange's Tier 18A market enters its fifth year of listing and the Science and Technology Innovation Board's fifth set of standards enters its fourth year. A total of 85 biotech companies have successfully gone public through this listing channel, driving the entire life science sector into high gear. After experiencing a boom and pursuit, as well as a cold winter and rationality, life science companies have never stopped innovating and breaking through. They continuously inject development momentum through technological innovation and bridge gaps through business model innovation. After going through dark moments, they still see themselves standing at new starting points and forging ahead.
From September 27th to 28th, Frost & Sullivan's (Frost & Sullivan, abbreviated as: Frost & Sullivan) second New Investment Expo and the 17th Frost & Sullivan Global Growth, Innovation, and Leadership Summit (abbreviated as 'Frost & Sullivan New Investment Conference') will be grandly held at the Shangri-La Hotel in Pudong, Shanghai. The conference will introducethe New Life Science Investment Summit Forumwith the theme of‘New Directions for the Future & Forward Marching’bringing togetherindustry leaders, life science companies, investment institutions, and professional service providersto focus on new opportunities in life science investment and financing, and jointly discuss the capital and industrial forces for companies to navigate cycles.
We sincerely invite you to attend this forum and embark on the successful journey of the capital market for life science companies!
Time:September 27th - 28th, 2023
Venue:Shangri-La Hotel in Pudong, Shanghai
Sponsors:Frost & Sullivan, China Biomedical Industry Chain Innovation and Transformation Alliance (CBIITA)
01
Guests
02
Forum Agenda
03
Guest Profiles
04
GIL Awards Presentation
The Frost & Sullivan Growth, Innovation, and Leadership Awards (GILA), based on the evaluation mechanism of the Frost & Sullivan Best Practice Awards, are rooted in China and aimed at the global market.
2023 marks the 62nd anniversary of Frost & Sullivan's global establishment and the 25th anniversary of entering the Chinese market. Frost & Sullivan China will continue to track and research a large number of successful cases in entrepreneurship and investment and financing in high-tech industries and strategic emerging industries within 2023, and conduct objective and in-depth analysis to comprehensively evaluate the innovation capabilities, business models, founding teams, technical capabilities, and development prospects of participating companies.
05
Blue Book Release
At this conference
Frost & Sullivan will grandly release
The '2023 Hong Kong Stock Exchange Tier 18A & Science and Technology Innovation Board Biotech Industry Development Blue Book'
Frost & Sullivan has compiled the '2023 Hong Kong Stock Exchange Tier 18A & Science and Technology Innovation Board Biotech Industry Development Blue Book' with the aim of sorting out the ecosystem and industrial development pattern of the biotech industry in the Hong Kong Stock Exchange's Tier 18A and Science and Technology Innovation Board markets for the Chinese industry community, and further providing cutting-edge insights to market participants. The release and exchange activities of the blue book will promote all parties in the market to deeply understand the development environment, technological development direction, market opportunities, etc., jointly draw future trends in the biotech field with all parties in the market, and work together to promote the sustainable development of the biotech industry.
06
Consultation for Participation
Registration Consultation | Business Cooperation | Media Cooperation
Contact Person:
Ms. Li 18917935734 (same WeChat)
Ms. Bai 18019047843 (same WeChat)
07
Highlights from the Previous Session
